Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594918 · ClinicalTrials.gov registry record · Phase 1
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Rahul Aggarwal.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01594918: Completed Phase 1 study, sponsored by Rahul Aggarwal.
NCT01594918 is a Phase 1 study that has completed, run by Rahul Aggarwal. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01594918, a Phase 1 study, has completed, sponsored by Rahul Aggarwal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone (CAMP) in combination at different dose levels and to determine the highest dose that does not cause bad side effects. The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Mitoxantrone
- DRUG Cabazitaxel
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-06-23 |
| Phase | Phase 1 |
What the finished NCT01594918 record still lists
NCT01594918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT01594918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01594918 about?
NCT01594918 is a clinical study titled "Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone (CAMP) in combination at different dose levels and to determine the highest dose that does not cause bad side effects. The investigators want to find out what effects, good and/or bad, CAMP has on patients a...
What is the current status of trial NCT01594918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-06. Estimated completion is 2017-06-23.
What interventions are being tested in trial NCT01594918?
The interventions under investigation include: Prednisone (DRUG), Mitoxantrone (DRUG), Cabazitaxel (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT01594918?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01594918's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia